Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Kevin Bowrin, Jean-Baptiste Briere, Pierre Levy, Mondher Toumi & Aurélie Millier. (2020) Use of real-world evidence in meta-analyses and cost-effectiveness models. Journal of Medical Economics 23:10, pages 1053-1060.
Read now
Read now
Masatsugu Hori, Norio Tanahashi, Sayako Akiyama, Grace Kiyabu, Julie Dorey & Rei Goto. (2020) Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation in the Japanese healthcare setting. Journal of Medical Economics 23:3, pages 252-261.
Read now
Read now
Jeffrey D Miller, Xin Ye, Gregory M Lenhart, Amanda M Farr, Oth V Tran, W Jackie Kwong, Elizabeth A Magnuson & William S Weintraub. (2016) Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US. ClinicoEconomics and Outcomes Research 8, pages 215-226.
Read now
Read now
Nicola Lucio Liberato & Monia Marchetti. (2016) Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review. Expert Review of Pharmacoeconomics & Outcomes Research 16:2, pages 221-235.
Read now
Read now
Christophe Dubois, Tom Adriaenssens, Lieven Annemans, Johan Bosmans, Britt Callebaut, Pascal Candolfi, Kristoff Cornelis, Alexis Delbaere, Michelle Green, Joelle Kefer, Patrizio Lancellotti, Michael Rosseel, Judith Shore, Jan Van Der Heyden, Sebastian Vermeersch & Eric Wyffels. Transcatheter aortic valve implantation versus surgical aortic valve replacement in severe aortic stenosis patients at low surgical mortality risk: a cost-effectiveness analysis in Belgium. Acta Cardiologica 0:0, pages 1-12.
Read now
Read now
Articles from other publishers (46)
Yan Li, Pingyu Chen, Xintian Wang, Qian Peng, Shixia Xu, Aixia Ma & Hongchao Li. (2023) Methods for Economic Evaluations of Novel Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review. Applied Health Economics and Health Policy.
Crossref
Crossref
Charles Okafor, Joshua Byrnes, Simon Stewart, Paul Scuffham & Clifford Afoakwah. (2023) Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review. PharmacoEconomics 41:8, pages 913-943.
Crossref
Crossref
Manon Belhassen, Olivier Hanon, Philippe Gabriel Steg, Isabelle Mahé, Mélanie Née, Flore Jacoud, Faustine Dalon, François-Emery Cotté, Dominique Guitard-Dehoux, Claire Marant-Micallef, Eric Van Ganse & Nicolas Danchin. (2022) Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France. The European Journal of Health Economics 24:6, pages 867-875.
Crossref
Crossref
Rini Noviyani, Sitaporn Youngkong, Surakit Nathisuwan, Bhavani Shankara Bagepally, Usa Chaikledkaew, Nathorn Chaiyakunapruk, Gareth McKay, Piyamitr Sritara, John Attia & Ammarin Thakkinstian. (2022) Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis. BMJ Evidence-Based Medicine 27:4, pages 215-223.
Crossref
Crossref
Derrick Y Tam, Paymon M Azizi, Stephen E Fremes, Joanna Chikwe, Mario Gaudino & Harindra C Wijeysundera. (2021) The cost-effectiveness of transcatheter aortic valve replacement in low surgical risk patients with severe aortic stenosis. European Heart Journal - Quality of Care and Clinical Outcomes 7:6, pages 556-563.
Crossref
Crossref
Shatha Alquraan & Feras Darwish El-Hajji. (2021) Cost-effectiveness analysis for the parenteral anticoagulants in Jordan. Journal of Pharmaceutical Health Services Research 12:3, pages 369-376.
Crossref
Crossref
Bruno Bregman, Siguroli Teitsson, Isabella Orsini, François-Emery Cotté, Adenike Amadi, Andriy Moshyk, Stéphane Roze & Anne-Françoise Gaudin. (2020) Cost–Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France. Dermatology and Therapy 10:6, pages 1331-1343.
Crossref
Crossref
Renato D. Lopes, Samantha E. Berger, Manuela Di Fusco, Amiee Kang, Cristina Russ, Abena Afriyie, Amy Earley, Sohan Deshpande & Lorenzo G. Mantovani. (2020) A review of global health technology assessments of non-VKA oral anticoagulants in non-valvular atrial fibrillation. International Journal of Cardiology 319, pages 85-93.
Crossref
Crossref
K. Bode, G. Hindricks, J. M. ten Berg & P. Whittaker. (2018) Anticoagulant plus antiplatelet therapy for atrial fibrillationAntikoagulation plus Thrombozytenaggregationshemmung bei Vorhofflimmern. Herz 45:6, pages 564-571.
Crossref
Crossref
Mustafa Oguz, Tereza Lanitis, Xiaoyan Li, Gail Wygant, Daniel E. Singer, Keith Friend, Patrick Hlavacek, Andreas Nikolaou & Soeren Mattke. (2019) Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USA. Applied Health Economics and Health Policy 18:4, pages 533-545.
Crossref
Crossref
Gérard de Pouvourville, Patrick Blin & Pierre Karam. (2019) The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France. The European Journal of Health Economics 21:2, pages 235-249.
Crossref
Crossref
Kevin Bowrin, Jean-Baptiste Briere, Laurent Fauchier, Craig Coleman, Aurélie Millier, Mondher Toumi, Emilie Clay & Pierre Levy. (2020) Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France. PLOS ONE 15:1, pages e0225301.
Crossref
Crossref
Ahmad S. Hersi, Katherine M. Osenenko, Sid Ahmed Kherraf, Ayman Abdel Aziz & Robert Joseph Sambrook. (2019) Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia. Annals of Saudi Medicine 39:4, pages 265-278.
Crossref
Crossref
Howard H. Z. Thom, Will Hollingworth, Reecha Sofat, Zhenru Wang, Wei Fang, Pritesh N. Bodalia, Peter A. Bryden, Philippa A. Davies, Deborah M. Caldwell, Sofia Dias, Diane Eaton, Julian P. T. Higgins, Aroon D. Hingorani, Jose A. Lopez-Lopez, George N. Okoli, Alison Richards, Chris Salisbury, Jelena Savović, Annya Stephens-Boal, Jonathan A. C. Sterne & Nicky J. Welton. (2019) Directly Acting Oral Anticoagulants for the Prevention of Stroke in Atrial Fibrillation in England and Wales: Cost-Effectiveness Model and Value of Information Analysis. MDM Policy & Practice 4:2, pages 238146831986682.
Crossref
Crossref
Thananan Rattanachotphanit, Chulaporn Limwattananon, Onanong Waleekhachonloet, Phumtham Limwattananon & Kittisak Sawanyawisuth. (2018) Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding. PharmacoEconomics 37:2, pages 279-289.
Crossref
Crossref
Xue Feng, Usha Sambamoorthi, Kim Innes, Traci LeMasters, Gregory Castelli, Nilanjana Dwibedi & Xi Tan. (2018) Healthcare Utilization and Expenditures in Working-Age Adults with Atrial Fibrillation: The Effect of Switching from Warfarin to Non-Vitamin K Oral Anticoagulants. American Journal of Cardiovascular Drugs 18:6, pages 513-520.
Crossref
Crossref
Alexa R. Hospodar, Kenneth J. Smith, Yuting Zhang & Inmaculada Hernandez. (2018) Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding. American Journal of Cardiovascular Drugs 18:4, pages 317-325.
Crossref
Crossref
Nai-Fang Chi, Ye Wang, Li-Nien Chien, Shu-Chen Chien & Yu Ko. (2018) Health Care Costs and Utilization of Dabigatran Compared With Warfarin for Secondary Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation. Medical Care 56:5, pages 410-415.
Crossref
Crossref
Derrick Y. Tam, Avery Hughes, Stephen E. Fremes, Saerom Youn, Rebecca L. Hancock-Howard, Peter C. Coyte & Harindra C. Wijeysundera. (2018) A cost-utility analysis of transcatheter versus surgical aortic valve replacement for the treatment of aortic stenosis in the population with intermediate surgical risk. The Journal of Thoracic and Cardiovascular Surgery 155:5, pages 1978-1988.e1.
Crossref
Crossref
Herbert J.A. Rolden, Gert Jan van der Wilt, Angela H.E.M. Maas & Janneke P.C. Grutters. (2018) THE GAP BETWEEN ECONOMIC EVALUATIONS AND CLINICAL PRACTICE: A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS ON DABIGATRAN FOR ATRIAL FIBRILLATION. International Journal of Technology Assessment in Health Care 34:3, pages 327-336.
Crossref
Crossref
George Gourzoulidis, Georgia Kourlaba, John Kakisis, Mitiadis Matsagkas, George Giannakoulas, Konstantinos I. Gourgoulianis, Theodoros Vassilakopoulos & Nikos Maniadakis. (2017) Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece. Clinical Drug Investigation 37:9, pages 833-844.
Crossref
Crossref
Pranas Šerpytis, Sigita Glaveckaitė & Mindaugas Lizaitis. (2017) HOSPITALIZACIJŲ IR GYDYMO ANALIZĖ ĮVYKUS VITAMINO K
ANTAGONISTŲ PERDOZAVIMUI. Sveikatos mokslai 27:3, pages 103-108.
Crossref
Crossref
Yazid Aoudia, Thitima Kongnakorn, Evie Merinopoulou, Mohamed Said Bettayeb & Sid Ahmed Kherraf. (2017) Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria. Journal of Health Economics and Outcomes Research 5:1, pages 39-54.
Crossref
Crossref
Kostas Athanasakis, Nadia Boubouchairopoulou, Eleftheria Karampli, Filippos Tarantilis, Paraskevi Savvari, Aikaterini Bilitou & John Kyriopoulos. (2016) Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective. American Journal of Cardiovascular Drugs 17:2, pages 123-133.
Crossref
Crossref
M. Ledroit, M. Megne Wabo, A. Berroneau, C. Mouton, Y. Pucheu, F. Xuereb & D. Breilh. (2017) Optimisation du bon usage des anticoagulants oraux directs (ACOD) via une démarche d’évaluation des pratiques professionnelles. Le Pharmacien Hospitalier et Clinicien 52:1, pages 51-57.
Crossref
Crossref
Inmaculada Hernandez, Kenneth J. Smith & Yuting Zhang. (2017) Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. Thrombosis Research 150, pages 123-130.
Crossref
Crossref
Stamatis J. Karakatsanis, Aikaterini Roumpi & Konstantinos N. Syrigos. (2016) The use of novel oral anticoagulants in cancer patients with venous thromboembolism. Seminars in Oncology 43:6, pages 655-665.
Crossref
Crossref
Carme Pinyol, Jose Mª Cepeda, Inmaculada Roldan, Vanesa Roldan, Silvia Jimenez, Paloma Gonzalez & Javier Soto. (2016) A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation. Cardiology and Therapy 5:2, pages 171-186.
Crossref
Crossref
Ying Jiao Zhao, Liang Lin, Hui Jun Zhou, Keng Teng Tan, Aik Phon Chew, Chee Guan Foo, Chia Theng Daniel Oh, Boon Peng Lim & Wee Shiong Lim. (2016) Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation. International Journal of Cardiology 220, pages 794-801.
Crossref
Crossref
Aristeidis H. Katsanos, Dimitris Mavridis, John Parissis, Spyridon Deftereos, Alexandra Frogoudaki, Agathi-Rosa Vrettou, Ignatios Ikonomidis, Maria Chondrogianni, Apostolos Safouris, Angeliki Filippatou, Konstantinos Voumvourakis, Nikos Triantafyllou, John Ellul, Theodore Karapanayiotides, Sotirios Giannopoulos, Anne W. Alexandrov, Andrei V. Alexandrov & Georgios Tsivgoulis. (2016) Novel oral anticoagulants for the secondary prevention of cerebral ischemia: a network meta-analysis. Therapeutic Advances in Neurological Disorders 9:5, pages 359-368.
Crossref
Crossref
Derk W Krieger. (2016) New insights into protecting the brain from the heart. Future Neurology 11:3, pages 201-205.
Crossref
Crossref
Anuj ShahAnand ShewaleCorey J. HayesBradley C. Martin. (2016) Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients. Stroke 47:6, pages 1555-1561.
Crossref
Crossref
Francois-Emery Cotté, Gwendoline Chaize, Anne-Françoise Gaudin, Adeline Samson, Alexandre Vainchtock & Laurent Fauchier. (2016) Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France. Europace 18:4, pages 501-507.
Crossref
Crossref
G. de Pouvourville. (2016) Anticoagulants d'action directe: une revue de la littérature des études coût/efficacité en Europe. Archives of Cardiovascular Diseases Supplements 8:2, pages 180-191.
Crossref
Crossref
G. de Pouvourville. (2016) Co?t de la prise en charge des accidents vasculaires c?r?braux en France. Archives of Cardiovascular Diseases Supplements 8:2, pages 161-168.
Crossref
Crossref
I. Durand-Zaleski. (2016) ?tudes co?t/efficacit?: id?es fausses et ?l?ments de m?thode. Archives of Cardiovascular Diseases Supplements 8:2, pages 157-160.
Crossref
Crossref
A. Cohen & C. Leclercq. (2016) Rapport coût/efficacité des traitements médicamenteux et interventionnels dans la fibrillation atriale. Archives of Cardiovascular Diseases Supplements 8:2, pages 144-156.
Crossref
Crossref
João Costa, Francesca Fiorentino, Daniel Caldeira, Mónica Inês, Catarina Lopes Pereira, Luís Pinheiro, António Vaz-Carneiro, Margarida Borges & Miguel Gouveia. (2015) Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in PortugalCost-effectiveness of new oral anticoagulants in Portuguese atrial fibrillation patients. Revista Portuguesa de Cardiologia (English Edition) 34:12, pages 723-737.
Crossref
Crossref
João Costa, Francesca Fiorentino, Daniel Caldeira, Mónica Inês, Catarina Lopes Pereira, Luís Pinheiro, António Vaz‐Carneiro, Margarida Borges & Miguel Gouveia. (2015) Custo‐efetividade dos novos anticoagulantes orais na fibrilhação auricular em Portugal. Revista Portuguesa de Cardiologia 34:12, pages 723-737.
Crossref
Crossref
Isao Kamae, Yoichiro Hashimoto, Yukihiro Koretsune, Norio Tanahashi, Tatsunori Murata, Hemant Phatak, Larry Z. Liu, Ann C. Tang, Peter Feng Wang & Ken Okumura. (2015) Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan. Clinical Therapeutics 37:12, pages 2837-2851.
Crossref
Crossref
Pierre Sabouret, Marie Bricard, Marie-Annick Hermann, Francois-Emery Cotté, Leyla Deret-Bixio & Sophie Rushton-Smith. (2015) Discrepancy between guidelines for stroke prevention in atrial fibrillation and practice patterns in primary care. The nationwide French AFIGP survey. Archives of Cardiovascular Diseases 108:11, pages 544-553.
Crossref
Crossref
H.‐C. Diener, J. L. Halperin, K. Fox & G. J. Hankey. (2015) Stroke prevention with rivaroxaban in higher‐risk populations with atrial fibrillation. International Journal of Clinical Practice 69:7, pages 743-756.
Crossref
Crossref
C. Bergerot. (2015) Fibrillation atriale et diab?te de type 2. M?decine des Maladies M?taboliques 9:4, pages 385-390.
Crossref
Crossref
Alexander Mensch, Stephanie Stock, Björn Stollenwerk & Dirk Müller. (2014) Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation. PharmacoEconomics 33:3, pages 271-283.
Crossref
Crossref
Thitima Kongnakorn, Tereza Lanitis, Lieven Annemans, Vincent Thijs, Marnix Goethals, Sophie Marbaix & Jean-Claude Wautrecht. (2014) Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin. Clinical Drug Investigation 35:2, pages 109-119.
Crossref
Crossref
Talitha I. Verhoef, William K. Redekop, Fazila Hasrat, Anthonius de Boer & Anke Hilse Maitland-van der Zee. (2014) Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings. American Journal of Cardiovascular Drugs 14:6, pages 451-462.
Crossref
Crossref